FN-1501 Inhibits Diffuse Large B-Cell Lymphoma Tumor Growth by Inducing Cell Cycle Arrest and Apoptosis.

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer with high rates of treatment resistance and relapse.
• Standard chemotherapy is ineffective in 30-50% of DLBCL patients, necessitating novel therapeutic strategies.
• FN-1501 is a dual inhibitor targeting cyclin-dependent kinases and Fms-like receptor tyrosine kinase 3.

Purpose of the Study:

• To investigate the anti-tumor efficacy of FN-1501 in DLBCL models.
• To elucidate the molecular mechanisms underlying FN-1501's anti-cancer effects.
• To assess the potential of FN-1501 as a therapeutic option for refractory/relapsed DLBCL.

Main Methods:

• In vitro studies utilized cell counting kit-8 assays, western blotting, and flow cytometry to assess proliferation, cell cycle, and apoptosis.
• In vivo efficacy was evaluated using a DLBCL xenograft tumor model.
• Signaling pathway analysis (MAPK, PI3K/AKT/mTOR) and rescue studies were performed.

Main Results:

• FN-1501 demonstrated dose- and time-dependent inhibition of DLBCL cell proliferation in vitro.
• FN-1501 induced G1/S phase cell cycle arrest and caspase-dependent apoptosis.
• In vivo, FN-1501 significantly reduced tumor volume and weight, prolonging progression-free survival.
• FN-1501 inhibited MAPK and PI3K/AKT/mTOR pathways, which mediate cell cycle arrest and apoptosis.

Conclusions:

• FN-1501 exhibits significant anti-tumor activity against DLBCL in both in vitro and in vivo models.
• The drug's mechanism involves inhibition of key cell survival pathways (MAPK, PI3K/AKT/mTOR).
• FN-1501 represents a potential new therapeutic agent for patients with relapsed or refractory DLBCL.